Reducing The Number Of Failures In Early Stage Development - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Reducing The Number Of Failures In Early Stage Development

Pharmaceutical Technology Europe
Volume 22, Issue 7

Phase 0 trials in practice

The first specific feasibility study of the Phase 0 strategy, outlined by guidelines from the FDA, was conducted by the US National Cancer Institute.4 The drug investigated was ABT-888, which preclinical studies had suggested inhibited Poly (ADP-ribose) polymerase (PARPs), thereby inhibiting DNA repair and potentiating the cytotoxicity of DNA-damaging agents.4 The Phase 0 results for ABT-888 were considered to have been helpful when planning for Phase I and further clinical studies. For example, the feasibility of twice daily oral dosing as well as proof of mechanism were shown and information was also generated on a potential study biomarker.4

Since the ABT-888 Phase 0 trial, other companies have embarked on similar types of studies; however, the results of these studies are not yet widely available. In addition, questions have been raised about the ethics of Phase 0 trials, since they are not designed to offer clinical benefit.8 This is particularly the case when it comes to oncology, since patients may be seriously ill. There may also be confusion from the subject about the goals of the trial since Phase 0 studies do not follow the traditional approach to clinical drug development. Some authors have suggested that volunteers may be incentivised to participate if Phase 0 trials are shown to reduce drug development time,4 but since few studies have been run it is not possible to verify this.

Although a number of Phase 0 trials are being conducted by the pharmaceutical industry, some supporters of exploratory studies believe that many companies are still avoiding this approach out of fear. In 2007, Colin Garner, the CEO of the UK microdosing service firm Xceleron, criticised companies for relying on gut feeling when rejecting the idea of Phase 0 trials, rather than factual information.9 He explained that Xceleron had worked on 40 different molecules and generated Phase I data for 11 of them. Furthermore, he concluded that there was very good correlation between microdose pharmacokinetic and pharmacologic pharmacokinetic properties. According to the interview, Phase I trials typically cost between $5 million to $10 million whereas microdosing studies were in the order of $500000.

Although Phase 0 is an additional cost on top of Phase 1, it can provide earlier information about a drug, which in turn will give pharma companies more confidence in the project and help them to be better prepared for future studies.


There is a need for new approaches to evaluate promising new drug candidates in a manner that rules out failures as early as possible in the drug development process. Both the European Medicines Agency and FDA have published position papers exploring new ideas and technologies in the field of drug development, and the FDA also runs its Critical Path Initiative to deal with the increasing difficulty and unpredictability of product development.10 Both agencies have recognised that Phase 0 trials offer a promising approach to better understanding a new drug before it enters Phase I trials and beyond. However, many companies are awaiting formal recommendations from the agencies before using Phase 0 trials as part of their drug development strategy.

Faiz Kermani is a freelance consultant and President of the Global Health Education Foundation, a 501 (c) (3), a non-profit charity that supports medical education and research projects in developing countries. He is a member of Pharmaceutical Technology Europe's Editorial Advisory Board.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology Europe,
Click here